Precigen, Inc. (PGEN)
NASDAQ:PGEN
Want to see PGEN full AI Analyst Report?
PGEN Stock Chart & Stats
$3.98
-$0.11(-8.33%)
At close: 4:00 PM EST
$3.98
-$0.11(-8.33%)
Day’s Range― - ―
52-Week Range$1.28 - $5.47
Previous CloseN/A
Volume729.99K
Average Volume (3M)3.21M
Market Cap
$1.58B
Enterprise Value$1.34B
Total Cash (Recent Filing)$56.25M
Total Debt (Recent Filing)$98.25M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Aug 10, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding356,511,000
10 Day Avg. Volume3,835,607
30 Day Avg. Volume3,214,160
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)60.91
Price to Sales (P/S)131.52
P/FCF Ratio-14.18
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue42.43
Enterprise Value/Gross Profit56.10
Enterprise Value/Ebitda-15.53
Forecast
1Y Price Target
$11.00Price Target Upside176.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$115.44M
Bulls Say, Bears Say
Bulls Say
Clinical Development And Label ExpansionAn ongoing redosing study is evaluating repeat treatment and could enable label expansion that broadens the eligible patient population.
Regulatory And Market ExpansionRegulatory filings in Europe combined with planned pediatric studies and extended intellectual property protection create multiple pathways for sustained market expansion.
ReimbursementPermanent J-code reimbursement for the therapy will reduce reimbursement uncertainty and lower upfront financial risk for institutions, supporting broader patient access and commercial uptake.
Bears Say
Concentration And Adoption RiskPersistent site activation bottlenecks could leave commercial performance dependent on a small number of high-volume providers, increasing vulnerability to uneven ordering patterns.
Limited Geographic ReachDifficulty activating community hospitals risks concentrating treatment in specialized centers, limiting patient access across broader geographic areas and slowing revenue diversification.
Site Activation BottleneckActivation of targeted integrated delivery networks and community hospitals remains the primary barrier to reaching most treating physicians and could limit overall uptake.
Precigen News
PGEN FAQ
What was Precigen, Inc.’s price range in the past 12 months?
Precigen, Inc. lowest stock price was $1.28 and its highest was $5.46 in the past 12 months.
What is Precigen, Inc.’s market cap?
Precigen, Inc.’s market cap is $1.58B.
When is Precigen, Inc.’s upcoming earnings report date?
Precigen, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 82 days.
How were Precigen, Inc.’s earnings last quarter?
Precigen, Inc. released its earnings results on May 13, 2026. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.034 by $0.014.
Is Precigen, Inc. overvalued?
According to Wall Street analysts Precigen, Inc.’s price is currently Undervalued.
Does Precigen, Inc. pay dividends?
Precigen, Inc. does not currently pay dividends.
What is Precigen, Inc.’s EPS estimate?
Precigen, Inc.’s EPS estimate is >-0.01.
How many shares outstanding does Precigen, Inc. have?
Precigen, Inc. has 356,511,000 shares outstanding.
What happened to Precigen, Inc.’s price movement after its last earnings report?
Precigen, Inc. reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.034. Following the earnings report the stock price went up 10.843%.
Which hedge fund is a major shareholder of Precigen, Inc.?
Currently, no hedge funds are holding shares in PGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precigen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (176.38% Upside)
$11.00 (176.38% Upside)
Blogger Sentiment
Bullish
PGEN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days <0.1%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
180.68%
12-Months-Change
Fundamentals
Return on Equity
-1768.51%
Trailing 12-Months
Asset Growth
7.64%
Trailing 12-Months
Company Description
Precigen, Inc.
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
PGEN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum for PAPZIMEOS with a rapid revenue ramp, broad payer coverage, expert endorsement, and promising clinical durability data — all signaling an impactful product launch. The company also faces near-term operational challenges including elevated quarter cash burn, increased SG&A tied to commercialization, timing of cash collections, and limited disclosure of granular conversion metrics. Management expects cash consumption to moderate in Q2 and projects runway to cash-flow breakeven by end-2026, which, together with the strong launch indicators, supports a constructive outlook.View all PGEN earnings summariesPGEN Stock 12 Month Forecast
Average Price Target
$11.00
▲(176.38% Upside)
Technical Analysis
MiMedx Group
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Immunome
―
Praxis Precision Medicines
―
Ownership Overview
35.58% Insiders
12.42% Mutual Funds
15.09% Other Institutional Investors
28.76% Public Companies and
Individual Investors